RTP Mobile Logo
Second Opinion: Urology Investigators Provide Their Perspectives on Challenging Practical Issues in Prostate Cancer Management
Released December 2015

Featuring perspectives from Dr Leonard G Gomella. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for urologists, medical and radiation oncologists and other healthcare providers involved in the treatment of prostate cancer.

    OVERVIEW OF ACTIVITY
    Prostate cancer is the most frequently diagnosed cancer in men, with more than 50% of all cases found in individuals aged 65 years or older. Among the 220,800 new diagnoses of prostate cancer estimated within the United States in 2015, more than 90% will be discovered in the local and regional stages of disease where 5-year survival estimates approach 100% with current therapeutic intervention. This statistic emphasizes the importance of early detection, the effectiveness of current treatments and the natural history of the disease.

    Significant interest has been shown in the development of multigene prognostic assays that can evaluate the unique biology of an individual’s cancer to allow for further refinement of risk and subsequently more informed treatment decisions. In recent years a number of novel agents have received FDA approval accompanied by multiple new indications in the disease, and a number of these efforts have proven successful and have yielded therapeutic options that are already available for use in the clinic. As such, additional resources are necessary to assist clinicians as they contend with the complexity of decision-making throughout the course of prostate cancer treatment from localized to advanced metastatic castration-resistant prostate cancer (CRPC). To bridge the gap between research and patient care, this video presentation by Dr Leonard G Gomella uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist urologists, medical and radiation oncologists and other healthcare providers involved in the treatment of prostate cancer with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Review the use of genomic signatures to refine the risk of recurrence for patients with localized prostate cancer, and use this information to guide clinical decision-making.
    • Recall research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve CRPC, and use this information to guide treatment planning for these patients.
    • Recognize the importance of performance status, symptom burden and site of disease in decisions on the use of sipuleucel-T for CRPC.
    • Appreciate recent Phase III trial data documenting the benefit of adding docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic disease.
    • Identify appropriate bone-targeted therapeutic approaches (eg, bisphosphonates, RANK-ligand inhibitors, radium-223) for patients with metastatic CRPC.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Presenting Faculty Member

    Leonard G Gomella, MD
    The Bernard W Godwin Professor of Prostate Cancer
    Chairman, Department of Urology
    Associate Director, Jefferson Sidney Kimmel Cancer Center
    Clinical Director, Jefferson Sidney Kimmel Cancer Center Network
    Editor-in-Chief
    Canadian Journal of Urology
    Philadelphia, Pennsylvania

    Advisory Committee: Abbott Laboratories, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Merck; Contracted Research: Astellas Pharma Global Development Inc.

    Moderator

    Judd W Moul, MD
    James H Semans, MD Professor of Surgery
    Division of Urologic Surgery
    Duke University Medical Center
    Durham, North Carolina

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals; Contracted Research: Astellas Pharma Global Development Inc; Speakers Bureau: Ferring Pharmaceuticals, Genomic Health Inc, Janssen Biotech Inc, Medivation Inc, Sanofi.

    Project Steering Committee Members

    Raoul S Concepcion, MD
    Director of the Advanced Therapeutic Center
    Urology Associates
    Nashville, Tennessee

    Advisory Committee, Consulting Agreements and Contracted Research: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals; Speakers Bureau: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genomic Health Inc, Janssen Biotech Inc, MDxHealth Inc, Medivation Inc, Sanofi.

    Thomas E Keane, MB, ChB
    Professor and Chairman
    Medical University of South Carolina
    Department of Urology
    Charleston, South Carolina

    Advisory Committee: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals, Janssen Biotech Inc.

    Adam S Kibel, MD
    Chief of Urology
    Brigham and Women’s Hospital
    Dana-Farber Cancer Center
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Profound Medical Corp; Consulting Agreements: Dendreon Pharmaceuticals Inc, Genomic Health Inc, MTG, Sanofi.

    Daniel W Lin, MD
    Professor and Chief of Urologic Oncology
    Department of Urology
    Bridges Endowed Professorship in Prostate Cancer Research
    University of Washington
    Seattle, Washington

    Contracted Research: Genomic Health Inc, Myriad Genetic Laboratories Inc; Research Grant: Hologic Inc.

    Neal D Shore, MD
    Medical Director
    Carolina Urology Research Center
    Myrtle Beach, South Carolina

    Advisory Committee: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Roche Laboratories Inc, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Oncology; Consulting Agreement: Mundipharma International Limited; Contracted Research: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Lilly, Mundipharma International Limited, Roche Laboratories Inc, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Oncology; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Genomic Health Inc.

    PROJECT CHAIRDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genomic Health Inc and Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2015
    Expiration date: December 2016

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Chapters:
00:00:01 - Introduction
00:01:51 - A patient with low-risk, low-volume localized prostate cancer 
00:19:44 - A patient with metastases and no prior androgen deprivation therapy (ADT) 
00:31:13 - An asymptomatic patient who develops metastases while receiving ADT for PSA-only disease 
00:49:52 - A patient with bone-only metastatic castration-resistant prostate cancer